Amorfix Life Sciences and PREVENT Sign Licensing Agreement on ALS Vaccine

Amorfix Life Sciences, a theranostics company, and Pan-Provincial Vaccine Enterprise (PREVENT), have entered into a licensing agreement on Amorfix’s lead ALS vaccines, reports Trading Markets. The vaccines have shown efficacy in animal models of ALS; PREVENT will now complete development and conduct clinical trials on them.

Click here to read more.

Share this: